 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «12345678910111213...212213» |
- || Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Clinical, Retrospective data, Review, Journal: Paxlovid for the treatment of COVID-19: a systematic review and meta-analysis. (Pubmed Central) - Sep 20, 2024
Paxlovid can be considered an effective therapeutic agent for treating patients with COVID-19.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Comprehensive Analysis of Omicron Subvariants: EG.5 Rise, Vaccination Strategies, and Global Impact. (Pubmed Central) - Sep 20, 2024
In the context of the evolving variants, the FDA has granted emergency use authorization for updated COVID-19 vaccines targeting circulating strains, reflecting the adaptability of vaccination strategies to address emerging challenges. This comprehensive overview provides a nuanced understanding of the diverse Omicron subvariants, their global impact, and the ongoing efforts to combat their spread through vaccination and therapeutic interventions.
- | Evusheld (cilgavimab/tixagevimab) / AstraZeneca, Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal, CAR T-Cell Therapy: Protracted coronavirus disease 2019 after chimeric antigen receptor-T cell therapy successfully treated with sequential multidrug therapy. (Pubmed Central) - Sep 20, 2024
The patient was diagnosed with protracted COVID-19 and was treated with remdesivir, molnupiravir, nirmatrelvir/ritonavir, and tixagevimab/cilgavimab. These treatments appeared to contribute to the improvement of protracted COVID-19.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Enrollment closed, Trial completion date, Trial primary completion date: RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms (clinicaltrials.gov) - Sep 19, 2024
P2, N=964, Active, not recruiting, Sponsor: Kanecia Obie Zimmerman
These treatments appeared to contribute to the improvement of protracted COVID-19. Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> Mar 2025 | Trial primary completion date: Jul 2025 --> Dec 2024
- ||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Trial completion: PAXLC: A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID. (clinicaltrials.gov) - Sep 18, 2024
P2, N=100, Completed, Sponsor: Harlan M Krumholz
Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> Mar 2025 | Trial primary completion date: Jul 2025 --> Dec 2024 Active, not recruiting --> Completed
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Enrollment closed, Trial completion date, Trial primary completion date: RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms (clinicaltrials.gov) - Sep 18, 2024
P2, N=964, Active, not recruiting, Sponsor: Kanecia Obie Zimmerman
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> Mar 2025 | Trial primary completion date: Jul 2025 --> Dec 2024
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection. (Pubmed Central) - Sep 18, 2024
This study supports the use of direct-acting antivirals (DAAs) for late-onset management of persistent SARS-CoV-2 infection in immunocompromised hosts. However, treatment courses likely require to be extended for maximal therapeutic benefit, calling for appropriately powered clinical trials to meet the specific needs of this patient group.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Comparing the effectiveness of molnupiravir and nirmatrelvir-ritonavir in non-hospitalized and hospitalized COVID-19 patients with type 2 diabetes: A target trial emulation study. (Pubmed Central) - Sep 18, 2024
However, treatment courses likely require to be extended for maximal therapeutic benefit, calling for appropriately powered clinical trials to meet the specific needs of this patient group. The use of nirmatrelvir-ritonavir may be preferred to molnupiravir for COVID-19 patients with T2DM and without contraindication to either treatment.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Xocova (ensitrelvir) / Shionogi
Journal: A comprehensive study of SARS-CoV-2 mfigain protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system. (Pubmed Central) - Sep 17, 2024
Moreover, we showed the putative molecular mechanism of resistance based on in silico molecular modelling. These findings have implications on the development of future generation Mpro inhibitors, will help to understand SARS-CoV-2 protease inhibitor resistance mechanisms and show the relevance of specific mutations, thereby informing treatment decisions.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Drug susceptibility and the potential for drug-resistant SARS-CoV-2 emergence in immunocompromised animals. (Pubmed Central) - Sep 17, 2024
Viruses isolated from drug-treated immunocompromised hamsters did not show reduced susceptibility to the drugs. Molnupiravir and nirmatrelvir remain effective in
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Preclinical, Journal: Nirmatrelvir and Molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 Omicron subvariants. (Pubmed Central) - Sep 17, 2024
In this study, we evaluated the efficacy of nirmatrelvir (PF-07321332) and other clinically significant SARS-CoV-2 antivirals against a diverse panel of SARS-CoV-2 variants, encompassing the newly identified Omicron subvariants XBB1.5 and JN.1, using live-virus antiviral assays. Our findings demonstrate that while the last Omicron subvariants exhibited heightened pathogenicity in our animal model, nirmatrelvir and other clinically relevant antivirals consistently maintained their efficacy against all tested variants, including the XBB1.5 subvariant.
- Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Nirmatrelvir/ritonavir standby treatment for International Travelers: CON (Convention Center - Room 353 (3rd Floor); In-Person-Only) - Sep 15, 2024 - Abstract #ASTMH2024ASTMH_422;
- Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Nirmatrelvir/ritonavir standby treatment for International Travelers: PRO (Convention Center - Room 353 (3rd Floor); In-Person-Only) - Sep 15, 2024 - Abstract #ASTMH2024ASTMH_421;
- Paxlovid (nirmatrelvir/ritonavir) / Pfizer
66 - Clinical Tropical Medicine Debates: COVID and Cholera Vaccines (Convention Center - Room 353 (3rd Floor); In-Person-Only) - Sep 15, 2024 - Abstract #ASTMH2024ASTMH_420;
This symposium will explore the use of Nirmatrelvir/ritonavir for standby treatment of COVID in international travelers and expanded use of vaccines for prevention of Cholera in a debate style format. Presenters will articulate a pro or con position around each issue followed by a panel discussion of the merits of each argument.
- | GC376 / Anivive, Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Xocova (ensitrelvir) / Shionogi
Journal: SARS-CoV-2 Mpro inhibitor identification using a cellular gain-of-signal assay for high-throughput screening. (Pubmed Central) - Sep 15, 2024
Presenters will articulate a pro or con position around each issue followed by a panel discussion of the merits of each argument. The SARS2 main protease enzyme, Mpro (also called 3C-like protease, 3CLpro), is a bona fide drug target as evidenced by potent inhibition with nirmatrelvir and ensitrelvir, the active components of the drugs Paxlovid and Xocova, respectively...In this assay, Mpro inhibits expression of a luciferase reporter, and 8,777 small molecules were considered hits by causing a gain in luciferase activity 3x SD above the sample field activity (6.8% gain-of-signal relative to 100
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Molnupiravir or nirmatrelvir-ritonavir reduce the likelihood of hospitalization and mortality in immunocompromised patients with Covid-19. (Pubmed Central) - Sep 13, 2024
The SARS2 main protease enzyme, Mpro (also called 3C-like protease, 3CLpro), is a bona fide drug target as evidenced by potent inhibition with nirmatrelvir and ensitrelvir, the active components of the drugs Paxlovid and Xocova, respectively...In this assay, Mpro inhibits expression of a luciferase reporter, and 8,777 small molecules were considered hits by causing a gain in luciferase activity 3x SD above the sample field activity (6.8% gain-of-signal relative to 100 No abstract available
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Nirmatreolvir-ritonavir (Paxlovid) leads to no reduction of symptoms or hospitalizations in vaccinated or unvaccinated high-risk adults with Covid-19. (Pubmed Central) - Sep 13, 2024
No abstract available No abstract available
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Retrospective data, Journal: Effectiveness of Paxlovid in the treatment of the SARS-CoV-2 Omicron variant infection in children with hematologic malignancies: a retrospective cohort study. (Pubmed Central) - Sep 12, 2024
No factor was found to be statistically significant in predicting re-positive test results based on the binary logistic regression analysis. Administering Paxlovid within 5 days of the diagnosis of the SARS-CoV-2 Omicron variant infection in children may effectively shorten the clearance time of the virus, but there is still the possibility the patients may have re-positive test results.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits. (Pubmed Central) - Sep 6, 2024
Administering Paxlovid within 5 days of the diagnosis of the SARS-CoV-2 Omicron variant infection in children may effectively shorten the clearance time of the virus, but there is still the possibility the patients may have re-positive test results. No abstract available
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Structural and virologic mechanism of the emergence of resistance to Mpro inhibitors in SARS-CoV-2. (Pubmed Central) - Sep 5, 2024
We generated SARS-CoV-2 variants resistant to three SARS-CoV-2 main protease (Mpro) inhibitors (nirmatrelvir, TKB245, and 5h), by propagating the ancestral SARS-CoV-2WK521WT in VeroE6TMPRSS2 cells with increasing concentrations of each inhibitor and examined their structural and virologic profiles...The replicability of SARS-CoV-2WK521A191T surpassed that of SARS-CoV-2WK521WT in the absence of 5h, confirming that A191T confers enhanced viral fitness. The present data should shed light on the understanding of the mechanism of SARS-CoV-2's drug resistance acquisition and the development of resistance-repellant COVID-19 therapeutics.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: FMOe: Preprocessing and Visualizing Package of the Fragment Molecular Orbital Method for Molecular Operating Environment and Its Applications in Covalent Ligand and Metalloprotein Analyses. (Pubmed Central) - Sep 5, 2024
We demonstrated fragmentation with IFIE analyses for the two following cases: (1) covalent cysteine-ligand bonding inside the SARS-CoV-2 main protease (Mpro) and nirmatrelvir (Paxlovid) complex and (2) the metal coordination inside a zinc-bound cyclic peptide...FMOe simplifies manual fragmentation, allowing users to experiment with various fragmentation patterns and perform in-depth IFIE analysis with high accuracy. In the future, our findings will provide valuable insight into complicated cases, such as ligand fragmentation in modality drug discovery, especially for medium-sized molecules and metalloprotein fragmentation around metals.
- || Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Review, Journal: Paxlovid (Nirmatrelvir/Ritonavir)-Induced Tacrolimus Toxicity in Organ Transplant Recipients - A Review on Drug Interactions Involving CYP3A Enzymes. (Pubmed Central) - Sep 5, 2024
Various recommendations have been proposed to prevent and mitigate the adverse events related to the DDI of Paxlovid and tacrolimus. Transplant physicians should be aware of this DDI and collaborate with clinical pharmacists on this issue.
- Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Paxlovid Utilization and Social Vulnerability: Trends in Connecticut from 2022-2023 (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_3121;
- S-892216 / Shionogi
In Vitro and in Vivo Antiviral Activity of S-892216, a Second-Generation Oral 3CLpro Inhibitor against SARS-CoV-2 (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2626;
- The Feasibility of Safely and Efficiently Administering Antivirals to Nursing Home Residents During COVID-19 Outbreaks is Impaired by Polypharmacy and Comorbidities. (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2101;
- Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Patient Reported Outcomes of Nirmatrelvir/Ritonavir Treatment for High-risk, Nonhospitalized Adults with Symptomatic COVID-19 (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1701;
- S-892216 / Shionogi
Therapeutic Effect of Delayed Treatment with a Second-Generation 3CL Protease Inhibitor S-892216 in Hamsters Infected with SARS-CoV-2 (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1699;
- Patient Characteristics and Management of COVID-19 Diagnosed in the Outpatient Setting (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1695;
- A Pharmacist-Run Treatment Decision Program for High-Risk Outpatients with Mild-Moderate COVID-19 at an Urban Veteran's Affairs Medical Center (Virtual) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1691;
- S-892216 / Shionogi
In Vitro Resistance Profiling of S-892216, a Second Generation SARS-CoV-2 3CLpro Inhibitor for the Treatment of COVID-19 (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1688;
- Development and Maintenance of a Pharmacist-Run COVID-19 Outpatient Treatment Clinic at a Veterans Affairs Hospital (Virtual) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1687;
- Outpatient Antiviral Treatment Among High-risk Patients with Mild to Moderate COVID-19 During the Omicron Surge (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1686;
- Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Nirmatrelvir versus Short-Course Remdesivir for Mild-to-Moderate COVID-19 in High Risk Hospitalized Patients: A Propensity Score-Matched Study (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1683;
- Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Nirmatrelvir-ritonavir and molnupiravir for the outpatient treatment of Covid-19: a population-based cohort study (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1679;
- Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Nirmatrelvir/Ritonavir in Immunocompromised Hosts: Use and Outcomes from a Cancer Center (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1674;
- Characteristics, Clinical Management, and Outcomes of Immunocompromised Patients Diagnosed with COVID-19 in the Outpatient Setting in France (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1650;
- SARS-CoV-2 Rebound during Acute Infection is Associated with Long COVID (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1641;
- Incidence of viral rebound in hospitalized COVID-19 patients (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_1584;
- Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Efficacy of nirmatrelvir-ritonavir in high-risk trial participants with prior SARS-CoV-2 infection or vaccination: a pooled analysis (411) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_747;
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer, PF-835231 / Pfizer
Journal: Design of novel and highly selective SARS-CoV-2 main protease inhibitors. (Pubmed Central) - Sep 3, 2024
Transplant physicians should be aware of this DDI and collaborate with clinical pharmacists on this issue. Utilizing a constrained cyclic peptide that locks the conformation between the P3 (Val) and P2 (Leu) residues, we identified a highly selective inhibitor that fills the P2 pocket occupied by the leucine residue sidechain of PF-00835231 and the dimethyl-3-azabicyclo-hexane motif in nirmatrelvir (PF-07321332)...The lead prototype compound 1 (MPro IC50 = 230
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Retrospective data, Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-world effectiveness and safety of nirmatrelvir-ritonavir (Paxlovid)-treated for COVID-19 patients with onset of more than 5 (Pubmed Central) - Sep 3, 2024
Utilizing a constrained cyclic peptide that locks the conformation between the P3 (Val) and P2 (Leu) residues, we identified a highly selective inhibitor that fills the P2 pocket occupied by the leucine residue sidechain of PF-00835231 and the dimethyl-3-azabicyclo-hexane motif in nirmatrelvir (PF-07321332)...The lead prototype compound 1 (MPro IC50 = 230 Paxlovid treatment within 10
- || Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Observational data, Retrospective data, Review, Journal: Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies. (Pubmed Central) - Sep 2, 2024
Among cohort studies of non-hospitalized adults with COVID-19, nirmatrelvir/ritonavir is effective against the composite outcome of severe COVID-19 independent of vaccination status. Further research and a reassessment of molnupiravir use among vaccinated adults are warranted.
- || Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Review, Journal: Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice. (Pubmed Central) - Sep 2, 2024
Particular attention is needed for drugs that are predominantly metabolised by cytochrome P450 3A4, are substrates of P-glycoprotein and have a narrow therapeutic index. Proper management of potential DDIs must balance the benefit of nirmatrelvir/ ritonavir to prevent severe disease with the risk of serious adverse events.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Observational data, Retrospective data, Journal: Supply of nirmatrelvir/ritonavir and molnupiravir for patients with COVID-19 in the first eight months since listing on the Australian Pharmaceutical Benefits Scheme: A retrospective observational study. (Pubmed Central) - Sep 2, 2024
The benefits that followed from prompt government action in approving and obtaining nirmatrelvir/ritonavir were therefore likely to be less than they could potentially have been. Governments should consider investing in quality improvement systems to ensure the best outcomes in terms of efficacy and safety.
- | ibuzatrelvir (PF-07817883) / Pfizer
Journal: A Structural Comparison of Oral SARS-CoV-2 Drug Candidate Ibuzatrelvir Complexed with the Main Protease (Mpro) of SARS-CoV-2 and MERS-CoV. (Pubmed Central) - Sep 1, 2024
In addition, we examined the reversibility of compound binding to both proteases, which is an important parameter in reducing off-target effects as well as the potential immunogenicity. The crystal structures of the ibuzatrelvir complexes with Mpro of SARS-CoV-2 and of MERS-CoV will further assist drug design for coronaviral infections in humans and animals.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Retrospective data, Journal: Clinical features and outcomes in kidney transplant recipients with COVID-19 pneumonia: a single center retrospective cohort study. (Pubmed Central) - Sep 1, 2024
Early use of antiviral drugs (paxlovid or molnupiravir) is associated with better therapeutic outcomes. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a limited impact on the short-term renal function of the KTRs with concurrent moderate or severe COVID-19 pneumonia.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Insights from a community-based survey on factors influencing acceptance and uptake of Paxlovid (nirmatrelvir and ritonavir) as a COVID-19 antiviral medication in Singapore. (Pubmed Central) - Aug 31, 2024
The majority of our respondents would take Paxlovid if it was prescribed to them, but a much smaller proportion would have the initiative to request for this. Key factors that may influence uptake are COVID-19 threat perceptions, trust in healthcare and government, and perceptions of the drug's side effects and cost.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Artificial intelligence-aiding lab-on-a-chip workforce designed oral [3.1.0] bi and [4.2.0] tricyclic catalytic interceptors inhibiting multiple SARS-CoV-2 protomers assisted by double-shell deep learning. (Pubmed Central) - Aug 28, 2024
The cyclic compound's specific halogen atom location enhances the nitrile catalytic head, which deactivates several viral protein targets. Initiating this lab-on-a-chip that is not susceptible to the aging process for creating clinical compounds can leverage a new path to many valuable drugs with speedy oral drug discovery, especially to defend the loss of vulnerable population and prevent multimorbidity that is susceptible to hidden viral persistence in the continuing aging times.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: New combined Inverse-QSAR and molecular docking method for scaffold-based drug discovery. (Pubmed Central) - Aug 27, 2024
Binding energies and interactions were analyzed and compared to those of the anti-SARS-CoV-2 inhibitor Nirmatrelvir...Molecular dynamics (MD) simulations demonstrated the stability of the PF9/Mpro complex over 300 ns of simulation. These predicted structures, reported here for the first time, warrant synthesis and further evaluation of their biological activity through in vitro and in vivo studies.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Xocova (ensitrelvir) / Shionogi
Journal: Differences in Treatment Patterns and Patient Characteristics Between COVID-19 Patients Treated with Nirmatrelvir/Ritonavir and Ensitrelvir in Japan. (Pubmed Central) - Aug 27, 2024
It has been suggested that NMV-r and ESV have been used differently in Japan because there might be gaps in the implementation periods and the evidence from clinical trials. We should use each oral agent appropriately and make different recommendations in the guidance in the near future.